Xilio Therapeutics Inc — Liquidità Trimestrale (NASDAQ:XLO) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Totale attivo 71.08 M103.72 M133.81 M133.69 M154.69 M Totale passività 53.48 M93.02 M126.74 M141.79 M119.41 M Patrimonio netto totale 17.6 M10.7 M7.07 M-8.1 M35.27 M Totale passività e patrimonio netto 71.08 M103.72 M133.81 M133.69 M154.69 M Debito totale ————— Indebitamento netto —————

Notizie

Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market

Xilio prevede deposito IND per terapia oncologica XTX501 a metà 2026

Xilio Therapeutics presenterà dati sulla terapia oncologica mascherata all’AACR

Xilio Therapeutics implements 1-for-14 reverse stock split

Xilio Therapeutics ottiene 35,8 milioni di dollari dall’esercizio di warrant

Xilio Therapeutics secures $35.8 million from warrant exercises

Gli EPS di Xilio Development hanno mancato le aspettative per 0,06$, il fatturato supera le previsioni

Xilio Development earnings missed by $0.06, revenue topped estimates

Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC - Slideshow (NASDAQ:XLO) 2025-11-11

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript